Name
BioPorto Diagnostics
What We Do
Severe Acute Kidney Injury (AKI) adversely impacts over 40% of pediatric patients with cardiovascular compromise and can be hard to identify with serum creatinine alone. ProNephro AKI™ (NGAL) is the first FDA-cleared test for assessing AKI risk in ICU patients 3 months to 22 years. A low NGAL result indicates a low risk of AKI, allowing for confident use of interventions such as fluids, diuretics, or nephrotoxic medications. Elevated NGAL values signal a high risk of developing AKI, triggering nephrology consults and interventions 2-3 days before serum creatinine rises.
Visit booth 1032 to learn how ProNephro AKI can improve AKI management in your patients and get an update on our adult clinical trial.
Visit booth 1032 to learn how ProNephro AKI can improve AKI management in your patients and get an update on our adult clinical trial.
Website
Categories
Cardiac, Critical Care
Address
117 Kendrick Street
Suite 300
NEEDHAM HEIGHTS, MA 02494
United States
Suite 300
NEEDHAM HEIGHTS, MA 02494
United States
Twitter